Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
jQe0AKbFEPAFL9xw
